Health-care companies rose sharply as traders rotated into defensive sectors. Kidney-care firm DaVita said its operations were impeded by a recent ransomware attack.
Drug giant Pfizer halted development of its experimental weight-loss pill, as the pharmaceutical company struggles to find a follow-up to its success in the Covid-19 era.
Novo Nordisk and Eli Lilly, weight-loss drug incumbents, rose sharply.
Write to Rob Curran at rob.curran@dowjones.com
(END) Dow Jones Newswires
April 14, 2025 17:09 ET (21:09 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.